替加环素单药治疗泛耐药鲍曼不动杆菌的疗效观察

Efficacy Observation of Tigecycline Monotherapy for Pan-resistant Acinetobacter baumannii

目的:观察替加环素单药治疗泛耐药鲍曼不动杆菌的临床疗效。方法:采用回顾性分析方法,选择2012年1月-2013年5月我院使用替加环素单药(20例)与经验性头孢哌酮/舒巴坦联合米诺环素(20例)治疗泛耐药鲍曼不动杆菌感染的重症患者临床资料,采用卡方检验,评价其临床疗效。结果:替加环素单药与头孢哌酮/舒巴坦联合米诺环素治疗泛耐药鲍曼不动杆菌的有效率分别为80%、50%(P<0.05)。结论:在治疗泛耐药鲍曼不动杆菌感染临床常用抗菌药物效果不佳时,可以考虑选择替加环素。

OBJECTIVE：To observe the clinical efficacy of tigecycline monotherapy for pan-drug resistant Acinetobacter baumannii. METHODS：Clinical data of severe patients with pan-drug resistant A. baumannii infection treated with tigecycline monotherapy（20 cases）or empirical treatment of cefoperazone/sulbactam（20 cases）were analyzed retrospectively in our hospital during Jan.2012-May. 2013. The chi-square test method was used to evaluate its clinical efficacy. RESULTS：Effective rates of tigecycline monotherapy or cefoperazone/sulbactam combined with minocycline were 80% and 50%（P〈0.05）. CONCLUSIONS：In the treatment of pan-resistant A. baumannii infection,tigecycline can be considered when the effect of commonly used antibiotics is poor.